Advertisement

Carglumic acid in hyperammonaemia due to organic acidurias: a profile of its use in the EU

  • Hannah A. BlairEmail author
Adis Drug Q&A
  • 30 Downloads

Abstract

Carglumic acid (N-carbamylglutamate; Carbaglu®), a structural analog of N-acetylglutamate, is an effective and generally well-tolerated option for the treatment of hyperammonaemia due to propionic, methylmalonic and isovaleric acidurias. These organic acidurias are linked to a group of autosomal recessive inherited disorders that are associated with secondary hyperammonaemia due to the inhibition of the urea cycle. Carglumic acid can be administered orally or through a nasogastric tube. In retrospective, observational studies and case series/reports, carglumic acid rapidly reduced plasma ammonia levels and improved clinical symptoms of hyperammonaemia. Carglumic acid is generally well tolerated, and, based on limited data, may be associated with fewer treatment-emergent adverse events when used in combination with ammonia scavengers than when either therapy is administered alone.

Notes

Acknowledgements

The manuscript was reviewed by: A. Chakrapani, Metabolic Medicine Department, Great Ormond Street Hospital, NHS Foundation Trust, London, UK; S. Yap, Department of Inherited Metabolic Disorders, Sheffield Children’s Hospital, NHS Foundation Trust, Sheffield, UK. During the peer review process, Orphan Europe–Recordati Group, the marketing-authorization holder of carglumic acid, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

H A. Blair is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

References

  1. 1.
    Lichter-Konecki U. Defects of the urea cycle. Transl Sci Rare Dis. 2016;1(1):23–43.Google Scholar
  2. 2.
    Ah Mew N, Payan I, Daikhin Y, et al. Effects of a single dose of N-carbamylglutamate on the rate of ureagenesis. Mol Genet Metab. 2009;98(4):325–30.CrossRefGoogle Scholar
  3. 3.
    Dercksen M, Ijlst L, Duran M, et al. Inhibition of N-acetylglutamate synthase by various monocarboxylic and dicarboxylic short-chain coenzyme A esters and the production of alternative glutamate esters. Biochim Biophys Acta. 2014;1842(12 Pt A):2510–6.CrossRefGoogle Scholar
  4. 4.
    Vockley J, Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet. 2006;142C(2):95–103.CrossRefGoogle Scholar
  5. 5.
    Baumgartner MR, Horster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.CrossRefGoogle Scholar
  6. 6.
    Fraser JL, Venditti CP. Methylmalonic and propionic acidemias: clinical management update. Curr Opin Pediatr. 2016;28(6):682–93.CrossRefGoogle Scholar
  7. 7.
    Auron A, Brophy PD. Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatr Nephrol. 2012;27(2):207–22.CrossRefGoogle Scholar
  8. 8.
    Manoli I, Myles J, Sloan JL, et al. A critical reappraisal of dietary practices in methylmalonic acidemia raises concerns about the safety of medical foods. Part 1: isolated methylmalonic acidemias (MMA). Genet Med. 2016;18(4):386–95.CrossRefGoogle Scholar
  9. 9.
    Myles JG, Manoli I, Venditti CP. Effects of medical food leucine content in the management of methylmalonic and propionic acidemias. Curr Opin Clin Nutr Metab Care. 2018;21(1):42–8.CrossRefGoogle Scholar
  10. 10.
    Carbaglu 200 mg dispersible tablets: EU summary of product characteristics. Puteaux: Orphan Europe SARL; 2018.Google Scholar
  11. 11.
    Valayannopoulos V, Baruteau J, Delgado MB, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study. Orphanet J Rare Dis. 2016;11:32.CrossRefGoogle Scholar
  12. 12.
    Chakrapani A, Valayannopoulos V, Segarra NG, et al. Effect of carglumic acid with or without ammonia scavengers on hyperammonaemia in acute decompensation episodes of organic acidurias. Orphanet J Rare Dis. 2018;13(1):97.CrossRefGoogle Scholar
  13. 13.
    Filippi L, Gozzini E, Fiorini P, et al. N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. Neonatology. 2010;97(3):286–90.CrossRefGoogle Scholar
  14. 14.
    Fernández de Miguel S, Gimeno Diaz de Atauri A, Torres Peral R, et al. N-carbamyl glutamate treatment in hyperammonaemia decompensated propionic acidaemia [in Spanish]. Ann Pediatr. 2009;71(6):579–80.Google Scholar
  15. 15.
    Levrat V, Forest I, Fouilhoux A, et al. Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia? Orphanet J Rare Dis. 2008;3:2.CrossRefGoogle Scholar
  16. 16.
    Soyucen E, Demirci E, Aydin A. Outpatient treatment of propionic acidemia-associated hyperammonemia with N-carbamoyl-l-glutamate in an infant. Clin Ther. 2010;32(4):710–3.CrossRefGoogle Scholar
  17. 17.
    Tuchman M, Caldovic L, Daikhin Y, et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res. 2008;64(2):213–7.CrossRefGoogle Scholar
  18. 18.
    Lama More RA, Morais López A, Magallares Garcia L, et al. Ammonia levels control during an episode of septic shock in a patient with propionic acidemia [abstract no. P-175]. J Inherit Metab Dis. 2014;37(Suppl 1):S89–90.Google Scholar
  19. 19.
    Jones S, Reed CA, Vijay S, et al. N-carbamylglutamate for neonatal hyperammonaemia in propionic acidaemia. J Inherit Metab Dis. 2008;31(Suppl 2):S219–22.CrossRefGoogle Scholar
  20. 20.
    Schwahn BC, Pieterse L, Bisset WM, et al. Biochemical efficacy of N-carbamylglutamate in neonatal severe hyperammonaemia due to propionic acidaemia. Eur J Pediatr. 2010;169(1):133–4.CrossRefGoogle Scholar
  21. 21.
    Lévesque S, Lambert M, Karalis A, et al. Short-term outcome of propionic aciduria treated at presentation with N-carbamylglutamate: a retrospective review of four patients. JIMD Rep. 2012;2:97–102.CrossRefGoogle Scholar
  22. 22.
    Gebhardt B, Dittrich S, Parbel S, et al. N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia. J Inherit Metab Dis. 2005;28(2):241–4.CrossRefGoogle Scholar
  23. 23.
    Abacan M, Boneh A. Use of carglumic acid in treatment of hyperammonemia during metabolic decompensation of patients with propionic acidaemia. J Inherit Metab Dis. 2013;109(4):S164.Google Scholar
  24. 24.
    Ah Mew N, McCarter R, Daikhin Y, et al. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics. 2010;126(1):e208–14.CrossRefGoogle Scholar
  25. 25.
    Gebhardt B, Vlaho S, Fischer D, et al. N-carbamylglutamate enhances ammonia detoxification in a patient with decompensated methylmalonic aciduria. Mol Genet Metab. 2003;79(4):303–4.CrossRefGoogle Scholar
  26. 26.
    Yap S, Leong HY, Abdul Aziz F, et al. N-carbamylglutamate Is an effective treatment for acute neonatal hyperammonaemia in a patient with methylmalonic aciduria. Neonatology. 2016;109(4):303–7.CrossRefGoogle Scholar
  27. 27.
    Khan A, Casey R, Ferreira P, et al. Mut(0)-methylmalonic acidemia: carglumic acid can help lower blood ammonia levels and allow for adequate protein intake [abstract no. P-270]. J Inherit Metab Dis. 2013;36(Suppl 2):S184–5.Google Scholar
  28. 28.
    Mohamed S, Alhashem A, Nazmi S, et al. The use of carglumic acid in the treatment of acute hyperammonemia associated with organic aciduria: a single center experience [abstract no. P-192]. J Inherit Metab Dis. 2018;41(Suppl 1):S126–7.Google Scholar
  29. 29.
    Kasapkara CS, Ezgu FS, Okur I, et al. N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia. Eur J Pediatr. 2011;170(6):799–801.CrossRefGoogle Scholar
  30. 30.
    Tummolo A, Melpignano L, Carella A, et al. Long-term continuous N-carbamylglutamate treatment in frequently decompensated propionic acidemia: a case report. J Med Case Rep. 2018;12(1):103.CrossRefGoogle Scholar
  31. 31.
    Kiykim E, Oguzhan O, Duman C, et al. Long-term use of carglumic acid in the management of hyperammonemia in patients with methylmalonic and propionic acidemias [abstract no. P-195]. J Inherit Metab Dis. 2018;41(Suppl 1):S127–8.Google Scholar
  32. 32.
    Burlina A, Cazzorla C, Zanonato E, et al. Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria. Mol Genet Metab Rep. 2016;8:34–40.CrossRefGoogle Scholar
  33. 33.
    Bosoi CR, Rose CF. Identifying the direct effects of ammonia on the brain. Metab Brain Dis. 2009;24(1):95–102.CrossRefGoogle Scholar
  34. 34.
    Orphan Europe. SSIEM 2018 sponsored satellite symposium 6: optimising long-term outcomes of patients with propionic and methylmalonic acidaemias. 2018. http://www.ssiem2018.org/satellite-symposia/. Accessed 3 Dec 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations